LanZhou Foci Pharmaceutical Co.,Ltd.
Simbol: 002644.SZ
SHZ
7.78
CNYTržna cena danes
68.3675
Razmerje P/E
-2.3694
Razmerje PEG
3.97B
Kapaciteta MRK
- 0.01%
Donos DIV
LanZhou Foci Pharmaceutical Co.,Ltd. (002644-SZ) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1413.19 | 406 | 398.5 | 374.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | -70.42 | -15.8 | 2 | -10.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 2046.86 | 441.8 | 526.5 | 390.8 | |||||||||||||||||
balance-sheet.row.inventory | 1526.12 | 369.7 | 350.4 | 258.8 | |||||||||||||||||
balance-sheet.row.other-current-assets | 74.04 | 21.3 | 15.7 | 10 | |||||||||||||||||
balance-sheet.row.total-current-assets | 5060.22 | 1238.9 | 1291.1 | 1034.6 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4211.94 | 1061.8 | 1066.8 | 1091.6 | |||||||||||||||||
balance-sheet.row.goodwill | 26.96 | 9 | 4.5 | 4.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 320.66 | 79.6 | 76.8 | 72 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 347.63 | 88.6 | 81.3 | 76.4 | |||||||||||||||||
balance-sheet.row.long-term-investments | 335.99 | 79.9 | 66.7 | 82.1 | |||||||||||||||||
balance-sheet.row.tax-assets | 205.41 | 53.6 | 52.4 | 51.1 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 54.24 | 5.3 | 28.4 | 16.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 5155.21 | 1289.2 | 1295.5 | 1317.5 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 10215.43 | 2528.1 | 2586.6 | 2352.1 | |||||||||||||||||
balance-sheet.row.account-payables | 1338.65 | 310.4 | 311 | 214.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 98.74 | 24.7 | 13.8 | 14.7 | |||||||||||||||||
balance-sheet.row.tax-payables | 130.95 | 35.1 | 69.4 | 47.6 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 14.55 | 1.3 | 0.5 | 0.8 | |||||||||||||||||
Deferred Revenue Non Current | 1056.95 | 261 | 278.2 | 295 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 10.03 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 19.4 | 5.8 | 110.9 | 4.5 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1174.53 | 292 | 322.1 | 349.8 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 3.23 | 1.3 | 0.5 | 0.8 | |||||||||||||||||
balance-sheet.row.total-liab | 3126.08 | 759.7 | 852.6 | 724.6 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 2042.63 | 510.7 | 510.7 | 510.7 | |||||||||||||||||
balance-sheet.row.retained-earnings | 3119.21 | 776.2 | 746.9 | 654.5 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1237.35 | 158.4 | 152 | 143.6 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 605.87 | 300.1 | 305.8 | 305.8 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 7005.06 | 1745.4 | 1715.4 | 1614.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 10215.43 | 2528.1 | 2586.6 | 2352.1 | |||||||||||||||||
balance-sheet.row.minority-interest | 84.28 | 23.1 | 18.6 | 12.9 | |||||||||||||||||
balance-sheet.row.total-equity | 7089.35 | 1768.4 | 1734 | 1627.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 10215.43 | - | - | - | |||||||||||||||||
Total Investments | 265.57 | 64.1 | 68.7 | 71.7 | |||||||||||||||||
balance-sheet.row.total-debt | 113.29 | 26 | 14.4 | 15.5 | |||||||||||||||||
balance-sheet.row.net-debt | -1299.9 | -380 | -382.1 | -359.4 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 58.12 | 68.1 | 105.9 | 93.5 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 3.63 | 52.5 | 49.5 | 48.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0.2 | 1 | 0.2 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -0.2 | -1 | -0.2 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 66.85 | -82.3 | -112.2 | -117 | |||||||||||||||||
cash-flows.row.account-receivables | 59.5 | 59.5 | -210.1 | -66.8 | |||||||||||||||||
cash-flows.row.inventory | -7.3 | -7.3 | -91.7 | -0.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -134.7 | 188.6 | -49.5 | |||||||||||||||||
cash-flows.row.other-working-capital | 14.64 | 0.2 | 1 | 0.2 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -71.03 | 27.4 | 29.1 | -13.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 57.56 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -8.98 | -22.5 | -41.5 | -32.8 | |||||||||||||||||
cash-flows.row.acquisitions-net | -15.45 | -15.5 | 3.9 | 74.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 8.95 | -6 | -2.1 | -3.9 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 7.98 | 8 | -3.9 | 38.1 | |||||||||||||||||
cash-flows.row.other-investing-activites | -15.17 | 1.8 | 0.8 | -32.8 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -22.66 | -34.2 | -42.8 | 42.6 | |||||||||||||||||
cash-flows.row.debt-repayment | -22.59 | -21.5 | -14.2 | -35.3 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | -1.65 | -27.9 | -5.1 | -61.4 | |||||||||||||||||
cash-flows.row.other-financing-activites | -11.1 | -1.3 | 3.9 | 3.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -50.87 | -25 | -15.5 | -93.4 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 25.84 | 0.7 | 0.7 | -0.2 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 9.86 | 7.2 | 14.8 | -39.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1376.43 | 396.3 | 387.7 | 372.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1366.56 | 389.1 | 372.9 | 412 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 57.56 | 65.7 | 72.4 | 11.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | -8.98 | -22.5 | -41.5 | -32.8 | |||||||||||||||||
cash-flows.row.free-cash-flow | 48.58 | 43.2 | 30.9 | -21 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1130.07 | 1163.1 | 1019.2 | 817.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 765.41 | 801.8 | 733 | 594.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 364.66 | 361.3 | 286.2 | 223.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 31.51 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 17.15 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 154.39 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -2.01 | -1.6 | -9.7 | 24.4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 262.09 | 262 | 129.4 | 134.6 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 1027.5 | 1063.8 | 862.3 | 729 | |||||||||||||||||
income-statement-row.row.interest-income | 2.93 | 5.4 | 7.5 | 10.2 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.2 | 0.7 | 0.9 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 154.39 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -2.01 | -1.6 | -12.4 | -1.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -2.01 | -1.6 | -9.7 | 24.4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -2.01 | -1.6 | -12.4 | -1.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.2 | 0.7 | 0.9 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 40.06 | 52.5 | 62.2 | 32.2 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 112.68 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 72.62 | 83.3 | 139.4 | 112.4 | |||||||||||||||||
income-statement-row.row.income-before-tax | 70.6 | 81.6 | 127 | 110.8 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 11.28 | 13.5 | 21.1 | 17.3 | |||||||||||||||||
income-statement-row.row.net-income | 58.12 | 67.2 | 108.7 | 93.3 |
Pogosto zastavljeno vprašanje
Kaj je LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) skupna sredstva?
LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) skupna sredstva so 2528102214.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 576952643.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.323.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 0.095.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.051.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.064.
Kaj je LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 67189706.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 26031519.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 261964435.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 365338610.000.